TetraLogic, 8% 15jun2024, USD
国内債券, Senior Unsecured
国内債券, Senior Unsecured
|
TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal ...
TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. In April 2014,Tetralogic Pharmaceuticals Corp acquired the entire share capital of Shape Pharmaceutical Inc.
|
|
|
|
|
|
|
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
167 970
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡